Virtual Library

 x 
My Library Virtual Library FAQ

Start Your Search

X. Du



Author of

  • +

    P2.09 - Poster Session 2 - Combined Modality (ID 213)

    • Event: WCLC 2013
    • Type: Poster Session
    • Track: Combined Modality
    • Presentations: 1
    • +

      P2.09-014 - Concomitant Chemoradiotherapy Using Docetaxel and Cisplatin for Unresectable Stage III Lung Squamous Cell Carcinoma (ID 2846)

      09:30 - 09:30  |  Author(s): X. Du

      • Abstract

      Background
      Concomitant chemoradiotherapy is the standard treatment of unresectable stage III non-small cell lung cancer (NSCLC). However, the optimal chemotherapy regimen is still controversial, particularly in lung squamous cell carcinoma. We have conducted a phase II clinical trial in a Chinese population to evaluate concomitant treatment using docetaxel/cisplatin chemotherapy and thoracic radiotherapy followed by docetaxel/cisplatin consolidation chemotherapy in unresectable stage III lung squamous cell carcinoma. The purpose of this study is to evaluate the feasibility and activity, and also assess its impact on progression-free survival (PFS).

      Methods
      A total of 32 patients were enrolled between January 2011 and January 2013. Patients received concomitant docetaxel 30mg/m[2] on day 1 and day 8, cisplatin 25mg/m[2] on day 1 to day 3 repeated every 3 weeks for 2 cycles and thoracic radiotherapy, followed by docetaxel/cisplatin for 2 cycles as consolidation therapy (docetaxel 60mg/m[2] on day 1, cisplatin 25mg/m[2] on day 1 to day 3 repeated every 3 weeks). Objective response rate according to the RECIST criteria was recorded and toxicity was evaluated using the NCI Common Toxicity Criteria. The Kaplan–Meier method was used to evaluate patient survival. Univariate analysis of patient characteristics and tumor responses was conducted using the Chi-square and Fisher’s exact test.

      Results
      Eight (25.0%) and 20 patients (62.5%) had a complete or partial response, respectively, while 3 patient’s disease remained stable and 1 patient had progression of the disease. The overall response rate (87.2%, 95% confidence interval (CI): 63–97%) exceeded the goal per study design. The median PFS was 11.0 months (95% CI: 5.6–16.4 months). This approach obtained likely better effects than history control group. Main toxicity (grade 3 or greater, %): neutropenia 10 (31.3%); thrombocytopenia 7 (21.9%); anaemia 8 (25.0%); nausea/vomiting 5 (15.6%); anorexia 7 (21.9%), dysphagia 4 (12.5%), radiation pneumonitis 3 (9.4%) and fatigue 4 (12.5%).

      Conclusion
      This data suggests that concomitant treatment with docetaxel/cisplatin and thoracic radiotherapy was well tolerated, with promising activity in a Chinese population with unresectable stage III lung squamous cell carcinoma. Although the data presented herewith appears promising, this study is relatively small, and more data from randomized trials are needed to further validate this regimen.

  • +

    P3.24 - Poster Session 3 - Supportive Care (ID 160)

    • Event: WCLC 2013
    • Type: Poster Session
    • Track: Supportive Care
    • Presentations: 1
    • +

      P3.24-017 - The Impact of Local Radiotherapy to the Primary Site for Patients with stage IV Non-Small Cell Lung Cancer (ID 1192)

      09:30 - 09:30  |  Author(s): X. Du

      • Abstract

      Background
      The prognosis of patients with non-small cell lung cancer and distant metastasis is poor. The aim of this study was to evaluate the value of local treatment to the primary site for patients with stage IV non-small cell lung cancer and oligometastatic disease at diagnosis, particularly the influence of local treatment to the primary site on prognosis.

      Methods
      From January 2004 to December 2011, 69 consecutive patients with stage IV non-small cell lung cancer treated with local palliative radiotherapy to the primary site were enrolled in this retrospective study. The prognosis factors including the patients’ general condition, disease characteristics and treatment factors were analysed. Patients were divided into two groups based on the number of distant metastases (Oligometastasis, OMT, 1-4 metastases; Polymetastasis, PMT, > 5 metastases). The relationship between the prognosis and treatment factors was explored. Overall survival was estimated using the Kaplan-Meier method, and prognostic factors were identified by univariate and multivariate analyses.

      Results
      The median overall survival was 14.1 (95%CI:7.3-20.8) months and the 1, 3-year overall survival rates were 53.0% and 9.0% , respectively. Gender, smoking index and performance status of Zubrod-ECOG-WHO were significantly associated with prognosis under univariate analysis. There was marginally significant associated with prognosis for those patients who received chemotherapy(P = 0.054) and received a sufficient dose of local palliative radiation to the primary site (at least 60Gy) (P = 0.063). On multiplicity analysis, chemotherapy and performance status retained significance. In the hierarchical analysis, patients who received at least 60 Gy of local radiotherapy to the primary site(P=0.048)(Fig 1.) and received chemotherapy (P= 0.041) achieved better overall survival in the OMT group.Figure 1

      Conclusion
      For non-small cell lung cancer with OMT, local aggressive treatment to the primary site may improve overall survival. Our results suggest that the selected non-small cell lung cancer patients with distant metastasis may benefit from aggressive local therapy.